Noonan Syndrome Clinical Trial
Official title:
Consequences of Noonan Syndrome/LEOPARD Syndrome Associated Shp2 Mutations on Different Signaling Pathways Activation: Relationship With Hormonal Sensitivity
Noonan and LEOPARD syndromes share, with variable severity, different clinical traits, notably craniofacial manifestations, cardiopathies, short stature, and juvenile cancers. The main genetic cause of these syndromes is missense mutation of the gene encoding the ubiquitous tyrosine phosphatase Shp2, found in more than half the patients with NS and in 80% of LS cases. Shp2 plays pivotal roles in development, growth, and metabolism by regulating key signalling pathways (Ras/Mitogen activated protein kinase (MAPK), Phosphoinositide-3 Kinases (PI3K)/Akt) in response to growth factors/hormones. Deregulation of these signalling pathways has been causally linked to NS and LS pathophysiology. This project aims at better understanding hormonal sensitivity abnormalities in patients with Noonan syndrome (NS) or LEOPARD syndrome (LS) caused by mutations of the tyrosine phosphatase Shp2. To reach this goal, the investigators will take advantage of different tissues (fibroblasts ± adipocytes) from patients with NS / LS compared to healthy controls. All patients will have a skin biopsy and only patients about to undergo surgery will have a adipose tissue biopsy.
The activation of different signaling pathways (Ras/MAPK, PI3K/Akt) in response to growth factors/hormones (growth hormone, insulin) in fibroblasts and/or in adipocytes from patients with NS or LS will be compared to those of healthy subjects. These data will be correlated to clinical, hormonal, and biochemical characteristics of patients ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01529944 -
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658
|
Phase 3 | |
| Completed |
NCT00452725 -
Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome
|
Phase 3 | |
| Recruiting |
NCT05761314 -
Solid Tumors in RASopathies
|
N/A | |
| Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
| Recruiting |
NCT06267807 -
Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders
|
N/A | |
| Enrolling by invitation |
NCT05308927 -
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
|
||
| Recruiting |
NCT04395495 -
RASopathy Biorepository
|
||
| Completed |
NCT01529840 -
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
|
Phase 3 | |
| Recruiting |
NCT06355622 -
Prevalence and Characterization of Pain in RASopathies
|
N/A | |
| Recruiting |
NCT05202210 -
Constitution of a Biological Collection to Study the Pathophysiology in Noonan Syndrome
|
||
| Completed |
NCT02713945 -
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome
|
Phase 3 | |
| Recruiting |
NCT05361811 -
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
|
N/A | |
| Completed |
NCT03435627 -
Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)
|
||
| Recruiting |
NCT05723835 -
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
|
Phase 3 | |
| Completed |
NCT01927861 -
Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome
|
Phase 3 | |
| Recruiting |
NCT04888936 -
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies
|
||
| Recruiting |
NCT06331117 -
Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies
|
N/A | |
| Completed |
NCT00960128 -
Observational Prospective Study on Patients Treated With Norditropin®
|
N/A | |
| Terminated |
NCT00351221 -
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
|
Phase 2 |